ライフサイエンスコーパス: multitarget

1 esistance-resistant antibiotics that involve multitargeting.

2 harmacological evaluation of a new family of multitarget 2,4-dihydropyrano[2,3-c]pyrazoles as dual GS

3 considered candidates for further exploring multitarget activities and the molecular basis of polyph

4 veral derivatives of carprofen, sharing this multitarget activity.

5 his non-ATP competitive kinase inhibitor has multitargeted activity, promoting mitotic arrest and apo

6 m of this work was to develop a new class of multitarget agents active both as broad-spectrum antivir

7 eimer's disease calls for the development of multitarget agents addressing key pathogenic processes.

8 NF-kappaB activation and their regulation by multitargeted agents in contrast to monotargeted agents,

9 -steroid sulfatase inhibitors (DASIs) and as multitargeting agents for hormone-independent tumors, su

10 not detected by either noninvasive test, the multitarget analysis of fecal DNA detected a greater pro

11 of adverse events did not differ between the multitarget and intravenous cyclophosphamide groups (50.

12 22584 (PTK/ZK; vatalanib), an orally active, multitargeted angiogenesis inhibitor, has shown tolerabi

13 We report the identification of multitarget anti-Alzheimer compounds designed by combini

14 Multitarget antiangiogenic tyrosine kinase inhibitors (T

15 tive flavonol ligands with the aim to obtain multitargeted anticancer agents.

16 is important for development of efficacious multitargeted anticancer drugs.

17 Multitargeted antifolate (MTA) is an investigational age

18 9 colon carcinoma cells was decreased by the multitargeted antifolate (MTA), LY231514.

19 cal isosteric C8-N9 bridged analogues of the multitargeted antifolate LY231514 were synthesized as in

20 Pemetrexed is a multitargeted antifolate with manageable toxicity and ha

21 ill potentiate the activity of pemetrexed, a multitargeted antifolate, in squamous cell carcinoma of

22 nsideration of hybrid compounds as potential multitarget antimalarials.

23 n contribute to the development of covalent, multitarget antipyroptotic compounds targeting molecular

24 Thus, in search of a multitarget antivascular treatment strategy for AML, we

25 Hence, we propose this multitarget approach as a new and promising strategy for

26 The multitarget approach has gained increasing acceptance as

27 An innovative multitarget approach is presented, targeting both voltag

28 n metastatic prostate cancer will comprise a multitargeted approach aimed at both the tumor cell and

29 A more direct means by which this multitargeted approach can be achieved is by identifying

30 everal pro-permeability proteins providing a multitargeted approach in RVO.

31 A multitargeted approach involving selective local antiang

32 In recent years, multitarget approaches directed toward inhibition of kin

33 volved in epileptogenesis, it is likely that multitargeted approaches are required for epilepsy preve

34 esponse supports the concept of combination, multitargeted approaches rather than traditional chemoth

35 The multitarget assay is useful as a diagnostic tool to conf

36 rdetella species isolates were tested in the multitarget assay.

37 Small trials of multitarget assays demonstrate a sensitivity for colorec

38 values, both of which were quantified with a multitarget bacterial disinfection model.

39 ducers, thus demonstrating the potential for multitarget biosensing and high-throughput/high-content

40 origin of patients suggest that sorafenib's multitarget capacity, including RAF kinase inhibition, m

41 This strategy, using multitarget carousel oblique angle deposition, offers th

42 Our data indicate that multitargeted combinatorial therapies targeting tumor ce

43 e solved if a therapeutic agent could have a multitarget, combinatorial selectivity, killing, or othe

44 M344 therefore serves as an example of how a multitargeting compound could be used to address the pol

45 ination of both activities in this family of multitarget compounds confers them a notable interest fo

46 Synthetic triterpenoids are multitarget compounds exhibiting promise as preventative

47 Development of multitarget compounds is a promising strategy to avoid t

48 A new class of multitarget compounds was synthesized by linking a novel

49 m single-target small molecule inhibitors to multitarget compounds.

50 eatment can be reduced by the application of multitarget compounds.

51 Herein we report on a novel series of multitargeted compounds obtained by linking together gal

52 is, and therapeutic effects of the family of multitargeted compounds that simultaneously disrupt func

53 the development of a universal nanopore for multitarget detection.

54 erefore, this also allows the development of multitarget devices using porous material for capturing

55 ns, our system offers a general approach for multitarget diagnostics at the point-of-care.

56 espread utility in point-of-care devices and multitarget diagnostics.

57 them to be sorted with high purity using the multitarget dielectrophoresis activated cell sorter (MT-

58 erative diseases requires the development of multitarget-directed drugs (MTDs).

59 reported molecules designed according to the multitarget-directed ligand paradigm to exert combined a

60 for Alzheimer's disease, in this paper, the multitarget-directed ligand paradigm was applied to the

61 macological profile in the design of a novel multitarget-directed ligand that is able to exert not on

62 roidal anti-inflammatory drug carprofen as a multitarget-directed ligand that simultaneously inhibits

63 and in vitro evaluation of a novel series of multitarget-directed ligands (MTDL) displaying both nano

64 or donepezil and diarylthiazole as potential multitarget-directed ligands for the treatment of Alzhei

65 binations whose selective synergy depends on multitarget drug activity.

66 the effector and interference moieties in a multitarget drug determines its use: selective killing o

67 P shows promising preclinical potential as a multitarget drug for the prevention and/or treatment of

68 evelopment, the discovery of non-hydroxamate multitarget drugs against specific MMPs is of foremost i

69 An earlier design of multitarget drugs was confined to macromolecular reagent

70 ce approaches to the computational design of multitarget drugs.

71 peutic benefits are likely attributed to its multitargeted effects on cerebrovascular patency and int

72 NA target with very high specificity using a multitarget ELISA-based specificity assay.

73 Multitarget FAAH/Cox blockade may provide a transformati

74 The new compounds are among the most potent multitarget FAAH/COX inhibitors reported so far in the l

75 n to the selective FGFR inhibitor BGJ398 and multitargeted FGFR inhibitor ponatinib.

76 estigated, such as telomerase, survivin, and multitarget fluorescence in situ hybridization, which ma

77 g complexes on p63 or NF-kappaB/Rel sites of multitarget gene promoters.

78 er 24 weeks of therapy, more patients in the multitarget group (45.9%) than in the intravenous cyclop

79 time to overall response was shorter in the multitarget group (difference, -4.1 weeks [CI, -7.9 to -

80 overall response incidence was higher in the multitarget group than in the intravenous cyclophosphami

81 minary mechanistic research of unprecedented multitargeting heterocyclic ferrociphenols bearing eithe

82 udy led to the identification of a promising multitarget hit compound (5b) exhibiting high hMAO B inh

83 timize the antitrypanosomatid profile of the multitarget hit compound B6 (1).

84 Our results indicate that a complex and multitargeted hsa-miRNA response occurs during CMV repli

85 IFN-gamma-induced class II transactivator, a multitarget immune modulator, resulting in increased ant

86 les are brain-penetrant and exhibit balanced multitargeted in vitro activity in the low muM range.

87 The result of such multitarget inhibition is potent inhibition of TB cell g

88 nt and selective Bcr-Abl inhibition and with multitargeted inhibition of Bcr-Abl and Src family kinas

89 then metronomic chemotherapy, overlaid with multitargeted inhibition of PDGFR and VEGFR, gave comple

90 we describe MK-2461, a novel ATP-competitive multitargeted inhibitor of activated c-Met.

91 aling how large-scale profiling can identify multitargeted inhibitors of specific, diverse kinases.

92 emia (T-ALL) samples and pave the way toward multitargeted JAK1 and JAK3 therapy in T-ALL.

93 es cancer cell invasion, while vandetanib, a multitarget kinase inhibitor, dose-dependently inhibits

94 The addition of the multitargeted kinase inhibitor midostaurin to standard c

95 Dasatinib is a novel, oral, multitargeted kinase inhibitor of BCR-ABL and SRC family

96 ne kinase inhibitors, including dasatinib (a multitargeted kinase inhibitor of BCR-ABL and Src family

97 Recently, the multitargeted kinase inhibitor sorafenib was shown to be

98 iruses, all of which can be amplified by the multitargeted kinase inhibitor sunitinib.

99 KW-2449 is a novel multitargeted kinase inhibitor that induces cytotoxicity

100 b is an orally bioavailable, small molecule, multitargeted kinase inhibitor that inhibits VEGF recept

101 hether the addition of midostaurin - an oral multitargeted kinase inhibitor that is active in patient

102 Dasatinib is a multitargeted kinase inhibitor that was recently approve

103 tion of a fluorine-18 analog of dasatinib, a multitargeted kinase inhibitor, are reported.

104 The efficacy of sorafenib, a multitargeted kinase inhibitor, in melanoma is still und

105 these two compounds emerged to be promising multitarget lead candidates worthy of further pursuit.

106 These compounds emerge as promising safe multitarget ligands for the further development of a the

107 and monoamine oxidase B (MAO B), a series of multitarget ligands was properly designed by linking the

108 d faster immunostaining protocols, and allow multitarget localization with primary IgGs from the same

109 work, we present an alternative system, the multitarget magnetic activated cell sorter (MT-MACS), wh

110 observed cytotoxic potency was ascribed to a multitarget mechanism of action accounting for hGAPDH in

111 l expansion in vivo and that this involves a multitarget mechanism that includes repression of IFN si

112 4503 alone is capable of regressing AML by a multitargeted mechanism and that the addition of bevaciz

113 2.6 for both linear quadratic and single-hit multitarget models.

114 ive prospective application, we identified a multitarget-modulating profile of de novo designed molec

115 and complementary approach is the design of multitargeted modulators simultaneously addressing multi

116 hia coli polysaccharide K5 [K5-N,OS(H)] as a multitarget molecule highly effective in inhibiting VEGF

117 that K5-N,OS(H) represents an antiangiogenic multitarget molecule with potential implications for the

118 itable as a scaffold for the design of novel multitargeted molecules.

119 acuity, motion direction discrimination, and multitarget motion comparison.

120 ctorial pathology and the development of new multitarget neuroprotective drugs is promising and attra

121 In vivo studies validating multitargeting of prostanoid receptors for achieving sup

122 Multitargeting of selected prostanoid receptors yielded

123 Using deep mutational scanning and multitarget optimization, we developed a germline-target

124 Here we report that BEZ235, a multitargeted pan-PI3K/dual-mTOR inhibitor, potently kil

125 The CDC developed a multitarget PCR assay to differentiate B. pertussis, B.

126 ity limitations might inhibit routine use of multitarget PCR for clinical diagnosis, focused testing

127 by using the discriminative features of this multitarget PCR.

128 species in 164 of 298 specimens tested with multitarget PCR; B. holmesii and Bordetella pertussis we

129 Of the 11 eyes subjected to PPV, the multitargeted PCR results for tuberculosis were positive

130 Consequently, it seems that multitargeted photoimmunotherapy should also be useful a

131 s hold important implications for the use of multitargeted PI3K inhibitors in the treatment of hemato

132 Vitreous fluid samples were subjected to multitargeted polymerase chain reaction (PCR) for a M. t

133 agents, which can be explained by potential multitargeted properties.

134 ip studies that led to the identification of multitargeted prototypes with activities as MT-stabilizi

135 MgPa adhesion gene and the 16S rRNA gene, a multitarget real-time (MTRT) PCR for the detection of MG

136 A multitarget real-time PCR (MRT-PCR) for detection of Chl

137 A novel multitarget real-time PCR (RT-PCR) assay for the rapid i

138 A multitarget real-time PCR assay with three targets, incl

139 We have developed a multitarget real-time TaqMan PCR assay capable of rapidl

140 bination of oral sunitinib, a small molecule multitargeted receptor tyrosine kinase (RTK) inhibitor,

141 Sunitinib is a multitargeted receptor tyrosine kinase inhibitor approve

142 Sunitinib is an oral, multitargeted receptor tyrosine kinase inhibitor of the

143 SU11248, a multitargeted receptor tyrosine kinase inhibitor of VEGF

144 with solid malignancies were treated with a multitargeted receptor tyrosine kinase inhibitor resulti

145 ABT-869 (a multitargeted receptor tyrosine kinase inhibitor) inhibi

146 with solid malignancies were treated with a multitargeted receptor tyrosine kinase inhibitor, result

147 or sequential administration of sunitinib, a multitargeted receptor tyrosine kinase inhibitor.

148 Effects of 4 multitargeted receptor tyrosine kinase inhibitors on reg

149 or 8 and 90 revealed that both compounds are multitargeted receptor tyrosine kinase inhibitors with l

150 ccumulated that one mechanism for Gbetagamma multitarget recognition is through an intrinsically flex

151 type 1 infection and no cirrhosis, a 12-week multitargeted regimen of ABT-450/r-ombitasvir and dasabu

152 Treatment with the multitargeted regimen of ombitasvir-ABT-450/r and dasabu

153 RNA targets of multitargeted RNA-binding proteins (RBPs) can be studied

154 In conclusion, the use of this multitarget RT-PCR approach increases specificity, while

155 eak investigations were used to evaluate the multitarget RT-PCR assay.

156 SU11657 is a multitargeted selective inhibitor of class III/V recepto

157 The unusual multitarget selectivity of leucettines may account for t

158 ge epidemiologic study, we developed a fast, multitarget, sensitive, and specific assay named the Res

159 . bolletii isolates previously identified by multitarget sequencing.

160 Analyzed by the single-hit multitarget (SHMT) model, F1, F5, and F7, like camptothe

161 activated in most cancers and operate within multitarget signaling pathways.

162 s include simple and efficient production of multitarget-specific molecules in Escherichia coli, impr

163 We developed a model to determine whether a multitarget stool DNA (MT-sDNA) test that detects colore

164 We compared a noninvasive, multitarget stool DNA test with a fecal immunochemical t

165 rsons at average risk for colorectal cancer, multitarget stool DNA testing detected significantly mor

166 testing, fecal immunochemical testing (FIT), multitarget stool DNA testing, flexible sigmoidoscopy wi

167 ood test, the fecal immunochemical test, the multitargeted stool DNA test, and the methylated SEPT9 D

168 ome a suitable option for development of new multitarget strategies for inhibiting RAS-dependent tumo

169 rylimidazoles provide tools to explore novel multitargeted strategies for AD and other neurodegenerat

170 ression can lead to the development of novel multitargeting strategies for intrahepatic cholangiocarc

171 We developed a multitarget strategy to synthesize dual peptides simulta

172 By initially applying this multitarget strategy to the pressing problem of hormone-

173 When the multitarget TaqMan assay (ISFtu2, 23kDa, and tul4) was c

174 sensitive and specific nature of this rapid multitarget TaqMan assay provides a valuable new tool th

175 t showed a modulation of activity during the multitarget task.

176 pounds, promising for the design of original multitarget therapeutic agents for treating neurodegener

177 y as time elapses, we suggest a stepwise and multitarget therapeutic approach for SIRS and sepsis.

178 A multitargeted therapeutic approach using a bile acid seq

179 should encourage further development toward multitargeted therapeutic intervention in HDBC.

180 In this context, the development of single multitargeted therapeutics directed against two or more

181 y represent a novel target in the search for multitargeted therapies based on the HSP90 chaperone sys

182 This has spurred the development of multitargeted therapies, including small molecules that

183 vel specific molecular leukemic effector for multitarget therapy in p190-BCR-ABL-expressing acute lym

184 Multitarget therapy provides superior efficacy compared

185 We assessed whether multitarget therapy with enfuvirtide, 2 reverse-transcri

186 with HCV genotype 1 infection and cirrhosis, multitargeted therapy with the use of three new antivira

187 images from a phase II study of sunitinib, a multitargeted TKI.

188 Rational development of multitargeted TKIs for prostate cancer requires improved

189 targeted therapies rather than non-specific, multitargeted treatments.

190 Multitargeted tyrosine kinase inhibition has recently sh

191 SU11248 is an oral, selective multitargeted tyrosine kinase inhibitor currently in Pha

192 FGFR2-mutated oral SCC who responded to the multitargeted tyrosine kinase inhibitor pazopanib.

193 The multitargeted tyrosine kinase inhibitor sorafenib is use

194 The novel multitargeted tyrosine kinase inhibitor sunitinib is use

195 Multitargeted tyrosine kinase inhibitor sunitinib reduce

196 Nilotinib, a recently approved multitargeted tyrosine kinase inhibitor targeting the BC

197 lity of sunitinib malate (SU11248), an oral, multitargeted tyrosine kinase inhibitor that blocks the

198 ial growth factor receptor 2, c-MET, and RET multitargeted tyrosine kinase inhibitor that has antiang

199 Sunitinib is a clinically approved multitargeted tyrosine kinase inhibitor that inhibits va

200 Sunitinib is an oral, multitargeted tyrosine kinase inhibitor that inhibits va

201 SU11657, a selective, oral, multitargeted tyrosine kinase inhibitor that targets FLT

202 Dasatinib (BMS-354825) is a multitargeted tyrosine kinase inhibitor that targets onc

203 Pazopanib, a multitargeted tyrosine kinase inhibitor, has recently be

204 lity and anticancer efficacy of sunitinib, a multitargeted tyrosine kinase inhibitor, in patients wit

205 Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor, which has shown

206 staurin (PKC412; N-benzoylstaurosporin) is a multitargeted tyrosine kinase inhibitor, with demonstrat

207 ated whether a multimodal strategy combining multitargeted tyrosine kinase inhibitors (MTKIs) and mic

208 The multitargeted tyrosine kinase inhibitors Crizotinib and

209 neuregulin, whereas the off-target effect of multitargeted tyrosine kinase inhibitors may be mediated

210 Sunitinib, a multitargeted tyrosine-kinase inhibitor, which is approv

211 will compare advantages and disadvantages of multitarget versus combination therapies, discuss potent

212 standard." Our aim was to assess the use of multitarget versus single-target PCR for the diagnosis o